RESEARCH PLATFORM FOR
THE MOON SHOTS PROGRAM
The Evolution of Cancer, Leukemia, and Immunity Post Stem cEll transplant (ECLIPSE) platform utilizes state-of-the-art technologies to discover and develop novel immunotherapies for patients with blood cancers. ECLIPSE is part of MD Anderson’s Therapeutics Discovery division, a unique group of clinicians, researchers and drug development experts working collaboratively to develop the next generation of targeted, immune- and cell-based therapies.
Our team works tirelessly to identify markers unique to hematologic cancer cells that can be used as targets for new therapies. Through deep integration with the Moon Shots® platforms, ECLIPSE is leveraging unmatched clinical insight to accelerate these therapies into the clinic for patients in need.
ECLIPSE Platform Leader
Jeffrey Molldrem, M.D.
Professor and Chair ad interim, Hematopoietic Biology and Malignancy; Professor of Stem Cell Transplantation and Cellular Therapy
An unparalleled, clinically annotated sample bank
ECLIPSE is unique because of our capacity to leverage our unparalleled 20-year clinically annotated sample bank from patients (and their stem cell donors) undergoing transplant for hematologic malignancies. Our sample bank is comprised of over 40,000 cryopreserved samples from patients at several time points pre- and post-transplant and at relapse. Utilizing state-of-the-art technologies such as next-gen sequencing, transcriptome profiling and multidimensional flow cytometry phenotyping, our scientists are seeking to identify differentially expressed target antigens on leukemia stem cells via identification of antigen specific T cells.
Our team is organized in three groups:
- Program Biology: malignant cell target discovery and profiling, in vivo clonal evolution, therapeutics validation and biomarker development
- Computational Biology/Immunogenomics: data mining and analyses, neoantigen and minor HA prediction, multidimensional and multiparameter data analyses, structural biology
- Lymphocyte Biology: T cell and B-cell clonotype analyses, single cell functional and genomic profiling, high dimensional flow cytometry profiling, serum antibodies and in vivo efficacy studies in PDX models
A drug discovery engine advancing the next generation of impactful cancer
Leveraging our unique approach to discover and develop therapies to improve
Uncovering New Treatment Targets
ECLIPSE – or Evolution of Cancer, Leukemia, and Immunity Post Stem cEll transplant – is one of the platforms launched by MD Anderson’s Moon Shots Program to provide unique expertise, technical support and novel infrastructure to enable impactful research projects. Jeffrey Molldrem, M.D., platform leader, addresses the platform’s work and its integration within the Therapeutics Discovery division.Learn more